ZymoGenetics retains buy rating from Merrill

Merrill Lynch analyst Hari Sambasivam retained ZymoGenetics, Inc. at buy on news of positive phase 3 rhThrombin data. The trial of recombinant human thrombin versus bovine thrombin met its primary endpoint of comparable percentage hemostasis at 10 minutes while efficacy data were not disclosed. Shares of the Seattle-based pharmaceutical company were down 78 cents, or 4.05%, at $18.46. (Nasdaq: ZGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.